Accepted Manuscript



Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy

Lucio Boglione, MD Amedeo De Nicolò, Chiara Simona Cardellino, Tina Ruggiero, Valeria Ghisetti, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio

PII: S1198-743X(14)00025-1

DOI: 10.1016/j.cmi.2014.07.009

Reference: CMI 24

To appear in: *Clinical Microbiology and Infection*

Received Date: 22 April 2014

Revised Date: 17 July 2014

Accepted Date: 20 July 2014

Please cite this article as: Boglione L, De Nicolò A, Cardellino CS, Ruggiero T, Ghisetti V, Cariti G, Di Perri G, D'Avolio A, Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy, *Clinical Microbiology and Infection* (2014), doi: 10.1016/j.cmi.2014.07.009.

TITLE: Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy.

Authors: Lucio Boglione*, Amedeo De Nicolò*, Chiara Simona Cardellino, Tina Ruggiero, Valeria Ghisetti, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio,

Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy

*both Authors contributed equally to this paper

Number of Figures and Tables: 1 and 1

Abbreviations: hepatitis C virus, HCV; chronic hepatitis C, CHC; pegylated interferon, PEG-IFN; ribavirin, RBV; telaprevir, TVR; boceprevir, BOC; boceprevir-S isomer, BOC-S; protease inhibitors, PIs; sustained virological response , SVR; breakthrough, BT;direct-acting antiviral agents, DAAs; non-structural, NS; resistance associated amino acid variants, RAVs; ultra-performance liquid chromatography with Tandem Mass detector, UPLC-MS/MS; high-performance liquid chromatography with UV detector, HPLC-UV; interleukin 28B, IL28B; null-responder, NR; partial responder, PR; relapse, REL; receiver-operating characteristic, ROC; area under the curve, AUC; three times a day, TID; pharmacokinetics, PK; therapeutic drug monitoring, TDM; inter quartile range, IQR;

Word count: (excluding references, tables and abstract): 993

Short title: boceprevir plasma concentration and virological breakthrough

Corresponding Author: Lucio Boglione, (MD); Tel. +39.011.4393802, Fax: +39.011.4393975; e-mail: lucio.boglione@unito.it

Funding:none

Competing interests: none declared

Ethical approved: not required